Literature DB >> 18386085

Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis.

E Force1, F Taberner, C Cabellos, S Ribes, A Domenech, F Tubau, P F Viladrich, F Gudiol.   

Abstract

Meropenem is a carbapenem antibiotic that is highly active against the pathogens causing meningitis. Results with meropenem in the experimental rabbit model of penumococcal meningitis have been controversial, and the possible role of renal dehydropeptidase I in meropenem efficacy has been suggested. The aim of this study was to determine the efficacy of meropenem in two meningitis models and the possible influence of the animal model over results. Two strains of Streptococcus pneumoniae with different susceptibility to beta-lactams have been used in a guinea pig model and the classical rabbit meningitis model. Meropenem was bactericidal at 6 h in the guinea pig model against both strains with a reduction of >4 log ufc/ml. In the rabbit model it was bactericidal at 6 h against the susceptible strain, but against the resistant 3/8 therapeutical failures were recorded at 6 h, being bactericidal at 24 h. In conclusion, meropenem has shown bactericidal activity in both experimental models. This work emphasises the importance of an adequate election of the animal model for the appropriate development of studies of antimicrobial efficacy. We believe that guinea pig should be considered the best choice among laboratory animal species when assessing meropenem efficacy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18386085     DOI: 10.1007/s10096-008-0492-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis.

Authors:  S R Norrby
Journal:  J Antimicrob Chemother       Date:  2000-01       Impact factor: 5.790

2.  Practice guidelines for the management of bacterial meningitis.

Authors:  Allan R Tunkel; Barry J Hartman; Sheldon L Kaplan; Bruce A Kaufman; Karen L Roos; W Michael Scheld; Richard J Whitley
Journal:  Clin Infect Dis       Date:  2004-10-06       Impact factor: 9.079

3.  Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.

Authors:  F Fitoussi; C Doit; K Benali; S Bonacorsi; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

4.  Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges.

Authors:  R Dagan; L Velghe; J L Rodda; K P Klugman
Journal:  J Antimicrob Chemother       Date:  1994-07       Impact factor: 5.790

5.  Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group.

Authors:  C M Odio; J R Puig; J M Feris; W N Khan; W J Rodriguez; G H McCracken; J S Bradley
Journal:  Pediatr Infect Dis J       Date:  1999-07       Impact factor: 2.129

6.  Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.

Authors:  P Cottagnoud; M Cottagnoud; F Acosta; L Flatz; F Kühn; A Stucki; J Entenza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-14       Impact factor: 3.267

7.  Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.

Authors:  R G Dacey; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

8.  A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group.

Authors:  E Schmutzhard; K J Williams; G Vukmirovits; V Chmelik; B Pfausler; A Featherstone
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

9.  Efficacy of meropenem in experimental meningitis.

Authors:  K Nairn; G L Shepherd; J R Edwards
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

10.  Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group.

Authors:  K P Klugman; R Dagan
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

View more
  4 in total

1.  Treatment of Drug-resistant Pneumococcal Meningitis.

Authors:  Nida Hameed; Allan R Tunkel
Journal:  Curr Infect Dis Rep       Date:  2010-07       Impact factor: 3.725

2.  Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis.

Authors:  E Force; F Taberner; C Cabellos; S Ribes; A Doménech; F Tubau; P F Viladrich; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-17       Impact factor: 3.267

3.  Mouse, but not human, ApoB-100 lipoprotein cholesterol is a potent innate inhibitor of Streptococcus pneumoniae pneumolysin.

Authors:  Kristin R Wade; Eileen M Hotze; David E Briles; Rodney K Tweten
Journal:  PLoS Pathog       Date:  2014-09-04       Impact factor: 6.823

4.  Quantitation of cytokine mRNA by real-time RT-PCR during a vaccination trial in a rabbit model of fascioliasis.

Authors:  Ana M Espino; Francheska Rivera
Journal:  Vet Parasitol       Date:  2009-12-22       Impact factor: 2.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.